Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
Moving an object from one location to another—picking and placing—is an ideal application for industrial robots due to the robots’ repeatability, throughput and favorable return on investment. It is ...
Supposing you were in the market for a prototype of a circuit board here in 2013 – what kind of process would you have to go through to get one? Certainly one that'd require one whole heck of a lot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results